Shares of Virios Therapeutics, Inc. (NASDAQ:VIRI – Get Free Report) traded down 14.8% during trading on Wednesday. The stock traded as low as $0.9010 and last traded at $1.04. Approximately 429,398 shares changed hands during mid-day trading, a decline of 59% from the average daily volume of 1,049,645 shares. The stock had previously closed at $1.22.
Virios Therapeutics Trading Up 1.0%
The company has a 50 day moving average of $1.56 and a 200 day moving average of $1.97. The firm has a market cap of $20.03 million, a price-to-earnings ratio of -3.85 and a beta of 1.58.
Virios Therapeutics Company Profile
Virios Therapeutics, Inc (NASDAQ: VIRI) is a clinical-stage biotechnology company focused on developing antiviral therapies for conditions it believes may be associated with the activation of latent herpesviruses. The company’s research has centered on the potential role of viral reactivation in chronic diseases and related inflammatory symptoms.
Virios’ lead investigational product candidate has been IMC-1, a fixed-dose combination of famciclovir, an antiviral medication, and celecoxib, an anti-inflammatory drug.
Featured Articles
- Five stocks we like better than Virios Therapeutics
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
- CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
- Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal?
- Duolingo’s User Growth Is Outpacing Bookings, But Is Its Strategy Paying Off?
Receive News & Ratings for Virios Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Virios Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
